Overview
- Discusses the role of mitochondrial dysfunction and the complex pathophysiological mechanisms associated with a growing number of illnesses
- Follows a scientific approach to asses the complex and heterogenious relationships between mitochondria and calcium, apoptosis, oxidative phosphorylation, Reactive Oxygen Species and anabolic pathways
- Discusses mitochondria as a valuable target for xenobiotics and its etiopathogenic role in neglected iatrogenic diseases, stimulating the use of existing knowledge for clinical applications, diagnosis and therapy
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 942)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
About this book
Mitochondria are far more than the “powerhouse” of the cell as they have classically been described. In fact, mitochondria biological activities have progressively expanded to include not only various bioenergetic processes but also important biosynthetic pathways, calcium homeostasis and thermogenesis, cell death by apoptosis, several different signal transduction pathways mainly related to redox control of gene expression and so on. This functional and structural complexity may undergo important derangements so to justify the definition of ‘mitochondrial medicine’, which should include all the clinical consequences of congenital or acquired mitochondrial dysfunctions. There are actually a growing number of studies which assign a significant pathogenic role to damaged mitochondria in different diseases: ischemia/reperfusion injury, neurodegenerative diseases, cancer with its dramatic sequelae (i.e, metastasis), metabolic syndrome, hyperlipidemias, just to mention a few of the most important pathologies. In this context, a further aspect that should not be disregarded is the interaction of pharmacological agents with mitochondria, not only in regard of the toxicological aspects but, above all, of the potential therapeutic applications. In fact, it is interesting to note that, while the properties of different so-called “mitoxicants” are well-known, the subtle linkages between drugs and mitochondria is still in need of a real pharmacological and therapeutic control at the clinical level. This lack of consideration can often lead to an underestimation of unwanted toxic effects but also of desirable therapeutic activities. A reevaluation of the potential clinical role of mitochondria could give a new light on some yet obscure aspects of human pathophysiology.
Similar content being viewed by others
Table of contents (20 chapters)
-
Front Matter
-
Physiology and Structure of Mitochondria
-
Front Matter
-
-
Physiology and structure of Mitochondria
-
Mitochondria and Disease
-
Front Matter
-
-
Mitochondria and disease
-
Mitochondria, Aging and Pharmacotoxicological Aspects
-
Front Matter
-
Editors and Affiliations
Accessibility Information
Accessibility information for this book is coming soon. We're working to make it available as quickly as possible. Thank you for your patience.
Bibliographic Information
Book Title: Advances in Mitochondrial Medicine
Editors: Roberto Scatena, Patrizia Bottoni, Bruno Giardina
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-94-007-2869-1
Publisher: Springer Dordrecht
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Science+Business Media B.V. 2012
Hardcover ISBN: 978-94-007-2868-4Published: 09 February 2012
Softcover ISBN: 978-94-024-0588-0Published: 23 August 2016
eBook ISBN: 978-94-007-2869-1Published: 08 March 2012
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: XII, 461
Topics: Biomedicine general, Cancer Research, Molecular Medicine, Pharmacology/Toxicology, Medical Biochemistry